

Title (en)
LOW ADENOSINE ANTI-SENSE OLIGONUCLEOTIDE AGENT, COMPOSITION, KIT AND TREATMENTS

Title (de)
ANTISENSE-OLIGONUKLEOTIDE MIT GERINGEM ADENOSINGEHALT, ZUBEREITUNG, KIT UND BEHANDLUNGSMETHODEN

Title (fr)
AGENT COMPRENANT DES OLIGONUCLEOTIDES ANTISENS A FAIBLE TENEUR EN ADENOSINE, COMPOSITION, TROUSSE ET TRAITEMENTS

Publication
EP 1102786 A4 20020306 (EN)

Application
EP 99939006 A 19990803

Priority
• US 9917712 W 19990803
• US 9521298 P 19980803

Abstract (en)
[origin: WO0009525A2] A composition comprises a nucleic acid comprising an oligo anti-sense to a target such as polypeptide(s) associated with an ailment afflicting lung airways, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixtures. Various formulations contain a requisite carrier, and optionally other additives and biologically active agents. The agent of the invention may be prepared by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) associated with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the mRNA segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepared by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the anti-sense oligonucleotides with a AUniversal base@. The agent, composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, allergy(ies) and/or inflammation, such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, pulmonary hypertension and bronchoconstriction, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), ischemic conditions including ischemia itself, and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastasis, etc., as well as all types of cancers with may metastasize or have metastasized to the lung(s), including breast and prostate cancer. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. The present agent is effectively administered preventatively, prophylactically or therapeutically by itself for conditions without known therapies, or as a substitute for, or in conjunction with, other therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject, so that the agent has direct access to the airways and the lungs.

IPC 1-7
A61K 6/00

IPC 8 full level
C07H 21/00 (2006.01); **C12N 15/113** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)
C07H 21/00 (2013.01); **C12N 15/113** (2013.01); **C12N 15/1138** (2013.01); **A61K 38/00** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/33** (2013.01); **C12N 2310/334** (2013.01)

Citation (search report)
• [XY] WO 9640162 A1 19961219 - UNIV EAST CAROLINA [US], et al
• [Y] WO 9811211 A2 19980319 - HYBRIDON INC [US]
• [A] WO 9535032 A1 19951228 - SCRIPPS RESEARCH INST [US], et al
• [A] WO 9310820 A1 19930610 - GILEAD SCIENCES INC [US]
• [A] WO 9312756 A2 19930708 - UNIV CALIFORNIA [US]
• [E] WO 9960166 A1 19991125 - ISIS PHARMACEUTICALS INC [US], et al
• [XY] NARAYANAN, R.: "The NK-kappaB transcription factor", STEIN, C.A. & KRIEG, A.M. 'APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY'. WILEY-LISS, NEW YORK, US; 1998; CHAPTER 12, pages 231 - 243, XP002185125
• [A] NICHOLS R ET AL: "A UNIVERSAL NUCLEOSIDE FOR USE AT AMBIGUOUS SITES IN DNA PRIMERS", NATURE, vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 492 - 493, XP000560346, ISSN: 0028-0836
• [A] OHTSUKA E ET AL: "AN ALTERNATIVE APPROACH TO DEOXYOLIGONUCLEOTIDES AS HYBRIDIZATION PROBES BY INSERTION OF DEOXYINOSINE AT AMBIGUOUS CODON POSITIONS", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol. 260, no. 5, 10 March 1985 (1985-03-10), pages 2605 - 2608, XP002031938
• [A] LOAKES D ET AL: "5-NITROINDOLE AS AN UNIVERSAL BASE ANALOGUE", NUCLEIC ACIDS RESEARCH, vol. 22, no. 20, 1994, pages 4039 - 4043, XP000999195, ISSN: 0305-1048
• [A] RAHMAN M SAYEEDUR ET AL: "Nebularine (9-2'-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenine in vivo and in vitro.", MUTATION RESEARCH, vol. 377, no. 2, 1997, pages 263 - 268, XP001024479, ISSN: 0027-5107
• [T] METZGER W JAMES ET AL: "Oligonucleotide therapy of allergic asthma.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 104, no. 2 PART 1, August 1999 (1999-08-01), pages 260 - 266, XP001024505, ISSN: 0091-6749
• See references of WO 0009525A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0009525 A2 20000224; **WO 0009525 A3 20000518**; AU 5337499 A 20000306; CA 2333901 A1 20000224; CN 1317009 A 20011010; EP 1102786 A2 20010530; EP 1102786 A4 20020306; HK 1042706 A1 20020823

DOCDB simple family (application)

US 9917712 W 19990803; AU 5337499 A 19990803; CA 2333901 A 19990803; CN 99809303 A 19990803; EP 99939006 A 19990803;
HK 02102614 A 20020408